Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, George Lau et al.|NEJM Evidence|2022Cited by 1.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Zhenggang Ren et al.|The Lancet|2023Cited by 1k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Funda Meric‐Bernstam et al.|New England Journal of Medicine|2023Cited by 530
Systemic therapies for intrahepatic cholangiocarcinomaRobin Kate Kelley, Andrew X. Zhu|Journal of Hepatology|2020Cited by 435
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423